Merck KGaA(ADR) Rating Increased to Buy at UBS AG (MKGAY)

By admin | 6 years ago

Merck KGaA(ADR) (NASDAQ: MKGAY) was upgraded by equities research analysts at UBS AG (NYSE: UBS) from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday.

A number of other analysts have also recently weighed in on MKGAY. Analysts at Societe Generale initiated coverage on shares of Merck KGaA(ADR) in a research note to investors on Thursday, May 10th. They set a “hold” rating on the stock. Separately, analysts at JPMorgan Chase (NYSE: JPM) downgraded shares of Merck KGaA(ADR) from a “neutral” rating to an “underweight” rating in a research note to investors on Tuesday, April 10th. Finally, analysts at BNP Paribas (EPA: BNP) downgraded shares of Merck KGaA(ADR) from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, April 5th.

Merck KGaA is operating in the pharmaceutical and chemical business sectors. The Pharmaceuticals business sector comprises innovative prescription drugs as well as over-the-counter products, and operates through three division: Merck Serono, which markets products used in oncology and treatment of autoimmune and inflammatory diseases, among others, Consumer Health Care, which markets products for everyday health protection and mobility, among others and Clinical Trials, engaged in conducting clinical trails.

About the author